British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon, cutting its shareholding to 4.2% in the world’s largest standalone consumer healthcare firm.

GSK says blood cancer drug meets primary goal in late-stage trial

GSK sold around 300 million shares in its spun-off unit at a price of 326 pence per share.